<DOC>
	<DOCNO>NCT03054402</DOCNO>
	<brief_summary>This study first human study investigate safety , tolerability pharmacokinetics explore pharmacodynamics ascend single dos BAY1834845 use placebo control , randomize , single center design .</brief_summary>
	<brief_title>First Human Study Investigate Safety , Tolerability , Pharmacokinetics Explore Pharmacodynamics BAY1834845</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<criteria>Healthy male subject Age : 18 50 year ( inclusive ) first screen visit Body mass index ( BMI ) : 18.5 ≤ BMI ≤ 30 kg/m² Clinically relevant finding physical examination Relevant diseases within last 4 week prior first study drug administration Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Use systemic topical medicine substance oppose study objective might influence within 4 week first study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>